Share this Article
Ozdemir H, Akinci E, Coskun F
Correspondence: Dr Emine Akinci, emineakinci@yahoo.com
ABSTRACT
INTRODUCTION We aimed to compare the effectiveness of intravenous piracetam with that of intravenous dimenhydrinate in the treatment of acute peripheral vertigo in the emergency department.
METHODS This double-blind study comprised a total of 200 patients, aged between 18 and 70 years, who had presented to the emergency department of Ankara Training and Research Hospital and were diagnosed with peripheral vertigo. Evaluation of the severity of the patients’ vertigo was performed using a visual analogue scale, before and after drug administration.
RESULTS Both drugs were found to be effective (p < 0.001) and had comparable effects (p < 0.474). Dimenhydrinate was also found to have about two times the side effects of piracetam. Drowsiness was found to be the most common side effect of these two drugs.
CONCLUSION Dimenhydrinate and piracetam have similar levels of effectiveness with regard to acute vertigo. We conclude that piracetam, which has fewer side effects than dimenhydrinate, better vestibular compensation, and is effective for both acute and chronic vertigo, could be more frequently used in the emergency treatment of acute vertigo.
Keywords: dimenhydrinate, emergency department, peripheral vertigo, piracetam
Singapore Med J 2013; 54(11): 649-652; http://dx.doi.org/10.11622/smedj.2013225
REFERENCES
| 1. Cesarani A, Alpini D, Monti B, Raponi G; ENT Department, University of Milan, Milan, Italy. The treatment of acute vertigo. Neurol Sci 2004; 25 (Suppl 1):S26-30. http://dx.doi.org/10.1007/s10072-004-0213-8 | ||||
| 2. Fernandes CM, Samuel J. The use of piracetam in vertigo. S Afr Med J 1985; 68:806-8. | ||||
| 3. Miszke A, Rapacz K. [Treatment of vertigo syndrome with Nootropil]. Otolaryngol Pol 1988; 42:312-7. Polish. | ||||
| 4. De?erli V, Çevik AA, Türkçüer ?, Korkmaz T. Comparison of intraveneous diazepam, dimenhydrinate and diphenhydramine on patients with acute peripheral vertigo in the emergency department: a randomized, double blind, clinical trial. Turk J Emerg Med 2007; 7:10-7. | ||||
| 5. Goldman B. In Tintinalli J, Stapczynski JS, et al. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. 7th edition. New York:McGr aw- Hill; 2011: 114 4 -52. | ||||
| 6. Hood D. Goeting NLM. Current approaches in vertigo. 1st ed. Dorset: Duphar Medical Relations; 1991: 58-63. | ||||
| 7. Lempert T, Gresty MA, Bronstein AM. Benign positional vertigo: recognition and treatment. BMJ 1995; 311:489-91. http://dx.doi.org/10.1136/bmj.311.7003.489 | ||||
| 8. Narita S, Kurose M, Kobayashi K, Himi T. [Study on 242 inpatients reporting vertigo and dizziness]. Nihon Jibiinkoka Gakkai Kaiho 2003; 106:21-7. Japanese. http://dx.doi.org/10.3950/jibiinkoka.106.21 | ||||
| 9. Uno A, Nagai M, Sakata Y, Moriwaki K, Kato T. [Statistical observation of vertigo and dizziness patients]. Nippon Jibiinkoka Gakkai Kaiho 2001; 104:1119-25. Japanese. http://dx.doi.org/10.3950/jibiinkoka.104.1119 | ||||
| 10. Arya AK, Nunez DA. What proportion of patients referred to an otolaryngology vertigo clinic have an otological cause for their symptoms? J Laryngol Otol 2008; 122:145-9. http://dx.doi.org/10.1017/S0022215107008559 | ||||
| 11. Leuner K, Kurz C, Guidetti G, Orgogozo JM, Müller WE. Improved mitochondrial function in brain aging and Alzheimer disease – the new mechanism of action of the old metabolic enhancer piracetam. Front Neurosci 2010; 4. pii: 44. | ||||
| 12. Akdo?an Ö, Arda HN, Bahar S, et al. Kronik vertigolu hastalarda oral pirasetam kullan?m?. Turk Arch Otolaryngol 2003; 41:139-45. | ||||
| 13. Oosterveld WJ. The effectiveness of piracetam in vertigo. Pharmacopsychiatry 1999; (32 Suppl 1):54-60. http://dx.doi.org/10.1055/s-2007-979238 | ||||
| 14. Froehling DA, Silverstein MD, Mohr DN, et al. Benign positional vertigo: incidence and prognosis in a population-based study in Olmsted County, Minnesota. Mayo Clin Proc 1991; 66:596-601. http://dx.doi.org/10.1016/S0025-6196(12)60518-7 | ||||
| 15. Cho EI, White JA. Positional vertigo: as occurs across all age groups. Otolaryngol Clin North Am 2011; 44:347-60. http://dx.doi.org/10.1016/j.otc.2011.01.006 | ||||
| 16. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 2005; 11:169-82. http://dx.doi.org/10.1111/j.1527-3458.2005.tb00268.x | ||||
| 17. Toupet M. [Managing vertigo and vertigo syndromes in the elderly]. Presse Med 2001; 30(25 Pt 1):1273-4. French. | ||||
| 18. Desloovere C. Medical treatment for vertigo. B-ENT 2008; 4(Suppl 8):59-62. | ||||